Profits down as MorphoSys invests in proprietary development
This article was originally published in Scrip
MorphoSys' net profits dropped by 32% to €9.0 million for the year ending December 31st, 2009, owing to increased R&D costs. Revenues grew by 13% to €81.0 million.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.